{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T00:45:18Z","timestamp":1794185118532,"version":"4.8.0"},"reference-count":143,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T00:00:00Z","timestamp":1602460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.neuropharm.2020.108352","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:45:32Z","timestamp":1601984732000},"page":"108352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1099,"special_numbering":"C","title":["Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease"],"prefix":"10.1016","volume":"190","author":[{"given":"Gabriella","family":"Marucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Buccioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Dal","family":"Ben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catia","family":"Lambertucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosaria","family":"Volpini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Amenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108352_bib1","first-page":"95","article-title":"Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter,in rodents: possible treatment of Alzheimer's disease","volume":"93","author":"Abe","year":"2003","journal-title":"J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuropharm.2020.108352_bib2","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1111\/ijcp.12374","article-title":"The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions","volume":"68","author":"Adler","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.neuropharm.2020.108352_bib3","first-page":"1","article-title":"A review of clinical treatment considerations of donepezil in severe Alzheimer's disease","author":"Adlimoghaddam","year":"2018","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.neuropharm.2020.108352_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jconrel.2016.09.017","article-title":"Recent expansion of pharmaceutical nanotechnologies and targeting strategies in the field of phytopharmaceuticals for the delivery of herbal extracts and bioactives","volume":"241","author":"Alexander","year":"2016","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.neuropharm.2020.108352_bib5","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3329\/sjps.v4i1.8878","article-title":"Polymers and permeation enhancers: specialized components of mucoadhesives","volume":"4","author":"Alexander","year":"2011","journal-title":"Stamford J. Pharm. Sci."},{"key":"10.1016\/j.neuropharm.2020.108352_bib6","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.3109\/03639045.2015.1011167","article-title":"A comparative study of chitosan and poloxamer based thermosensitive hydrogel for the delivery of PEGylated melphalan conjugates","volume":"41","author":"Alexander","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.neuropharm.2020.108352_bib7","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ejmech.2014.05.056","article-title":"Synthesis and anti-cholinesterase activity of new 7-hydroxycoumarin derivatives","volume":"82","author":"Alipour","year":"2014","journal-title":"Eur. J. Med. Chem."},{"issue":"118","key":"10.1016\/j.neuropharm.2020.108352_bib9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejps.2018.03.025","article-title":"Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA","volume":"15","author":"Amenta","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2020.108352_bib10","doi-asserted-by":"crossref","first-page":"S281","DOI":"10.3233\/JAD-140150","article-title":"The ASCOMALVA (association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in alzheimer's disease) trial: interim results after two years of treatment","volume":"42","author":"Amenta","year":"2014","journal-title":"J Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108352_bib11","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0047-6374(01)00310-4","article-title":"Treatment of cognitive dysfunction associated with Alzheimer's disease with cholinergic precursors. Ineffective treatments or inappropriate approaches?","volume":"122","author":"Amenta","year":"2001","journal-title":"Mech. Ageing Dev."},{"issue":"17","key":"10.1016\/j.neuropharm.2020.108352_bib12","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1016\/j.bmc.2015.07.058","article-title":"Galantamine derivatives with indole moiety: docking, design, synthesis and acetylcholinesterase inhibitory activity","volume":"23","author":"Atanasova","year":"2015","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib13","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1678581","article-title":"Current and future treatments in Alzheimer's disease","volume":"39","author":"Atri","year":"2019","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/j.1471-4159.2009.06490.x","article-title":"A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease","volume":"112","author":"Bailey","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib15","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0306-4522(00)00180-9","article-title":"Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors","volume":"99","author":"Barnes","year":"2000","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108352_bib16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1126\/science.7046051","article-title":"The cholinergic hypothesis of geriatric memory dysfunction","volume":"217","author":"Bartus","year":"1982","journal-title":"Science"},{"key":"10.1016\/j.neuropharm.2020.108352_bib17","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejmech.2013.12.028","article-title":"Design, synthesis, pharmacological evaluation, QSAR analysis, molecular modeling and ADMET of novel donepezil-indolyl hybrids as multipotent cholinesterase\/monoamine oxidase inhibitors for the potential treatment of Alzheimer's disease","volume":"75","author":"Bautista-Aguilera","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0089454","article-title":"Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease","volume":"9","author":"Bhattacharya","year":"2014","journal-title":"PloS One"},{"key":"10.1016\/j.neuropharm.2020.108352_bib19","first-page":"CD001191","article-title":"Rivastigmine for Alzheimer's disease","volume":"4","author":"Birks","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2020.108352_bib20","article-title":"Donepezil for dementia due to Alzheimer's disease","volume":"6","author":"Birks","year":"2018","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2020.108352_bib21","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/cn5003539","article-title":"Dihydroquinoline carbamate derivatives as \u201cbiooxidizable\u201d prodrugs for brain delivery of acetylcholinesterase inhibitors: [11C] radiosynthesis and biological evaluation","volume":"6","author":"Bohn","year":"2015","journal-title":"Chem. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108352_bib22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40261-015-0296-4","article-title":"A novel once-daily fixed-dose combination of memantine extended release and donepezil for the treatment of moderate to severe Alzheimer's disease: two phase I studies in healthy volunteers","volume":"35","author":"Boinpally","year":"2015","journal-title":"Clin. Drug Invest."},{"issue":"24","key":"10.1016\/j.neuropharm.2020.108352_bib23","doi-asserted-by":"crossref","first-page":"8251","DOI":"10.1021\/jm200853t","volume":"54","author":"Bolea","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib147","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s00228-013-1483-y","article-title":"A population based study of dosing and persistence with anti-dementia medications","volume":"69","author":"Brewer","year":"2013","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2020.108352_bib24","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000086613","article-title":"Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease","volume":"20","author":"Brodaty","year":"2005","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.neuropharm.2020.108352_bib25","doi-asserted-by":"crossref","first-page":"7869","DOI":"10.1021\/acs.joc.7b01062","article-title":"The synthesis of certain derivatives and analogues of (\u2212)- and (+)-Galanthamine and an assessment of their capacities to inhibit acetylcholine esterase","volume":"82","author":"Buckler","year":"2017","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib26","first-page":"3364","article-title":"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders","volume":"367","author":"Campos","year":"2012","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3233\/JAD-160675","article-title":"The effect of the association between donepezil and choline alphoscerate on behavioral disturbances in alzheimer's disease: interim results of the ASCOMALVA trial","volume":"56","author":"Carotenuto","year":"2017","journal-title":"J Alzheimers Dis."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2020.108352_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2007.06.053","article-title":"N1phenethyl-norcymserine, a selective butyrylcholinesterase inhibitor, increases acetylcholine release in rat cerebral cortex: a comparison with donepezil and rivastigmine","volume":"572","author":"Cerbai","year":"2007","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib29","first-page":"CD001499","article-title":"Physostigmine for Alzheimer's disease","author":"Coelho","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.neuropharm.2020.108352_bib30","first-page":"55","article-title":"A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease","volume":"1","author":"Corey-Bloom","year":"1998","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108352_bib31","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","article-title":"AD2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial","volume":"363","author":"Courtney","year":"2004","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib32","first-page":"109\u2010115","article-title":"Defining disease modifying therapy for alzheimer's disease","volume":"4","author":"Cummings","year":"2017","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib33","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/00002093-200304000-00011","article-title":"Inhibition of human cholinesterases by drugs used to treat Alzheimer disease","volume":"17","author":"Darvesh","year":"2003","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2020.108352_bib34","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.2147\/DDDT.S86463","article-title":"A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease","volume":"10","author":"Deardorff","year":"2016","journal-title":"Drug Des. Dev. Ther."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108352_bib35","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1586\/14737175.5.5.563","article-title":"Rivastigmine for Alzheimer's disease","volume":"5","author":"Desai","year":"2005","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.neuropharm.2020.108352_bib36","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2018.01.066","article-title":"Design, synthesis and pharmacological evaluation of N-benzyl-piperidinyl-aryl-acylhydrazone derivatives as donepezil hybrids: discovery of novel multi-target anti-alzheimer prototype drug candidates","volume":"147","author":"Dias Viegas","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1254\/jphs.FPE05006X","article-title":"Effects of galantamine and donepezil on active and passive avoidance tests in rats with induced hypoxia","volume":"101","author":"Dimitrova","year":"2006","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108352_bib38","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.trci.2019.03.004","article-title":"The role of acetylcholinesterase inhibitors such as neostigmine and rivastigmine on chronic pain and cognitive function in aging: a review of recent clinical applications","volume":"5","author":"Eldufani","year":"2019","journal-title":"Alzheimer's Dementia"},{"issue":"11","key":"10.1016\/j.neuropharm.2020.108352_bib39","doi-asserted-by":"crossref","first-page":"272","DOI":"10.9740\/mhc.n106739","article-title":"Donepezil 23 mg: is it more advantageous compared to the original?","volume":"1","author":"English","year":"2012","journal-title":"Ment. Health Clin."},{"key":"10.1016\/j.neuropharm.2020.108352_bib40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0079-6123(08)62429-2","article-title":"Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease","volume":"98","author":"Enz","year":"1993","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108352_bib41","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.neuropharm.2004.04.009","article-title":"Co-administration of memantine has not effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain","volume":"38","author":"Enz","year":"2004","journal-title":"Neurofarmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib42","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/14756366.2019.1689237","article-title":"Novel tacrine-benzofuran hybrids as potential multi-target drug candidates for the treatment of Alzheimer's Disease","volume":"35","author":"Fancellu","year":"2020","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"15","key":"10.1016\/j.neuropharm.2020.108352_bib43","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2165\/00003088-200342150-00005","article-title":"Clinical pharmacokinetics of galantamine","volume":"42","author":"Farlow","year":"2003","journal-title":"Clin. Pharmacokinet."},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108352_bib44","doi-asserted-by":"crossref","DOI":"10.1111\/cns.12158","article-title":"24-week, randomized, controlled trial of rivastigmine patch 13.3 mg\/24 h versus 4.6 mg\/24 h in severe Alzheimer's dementia","volume":"19","author":"Farlow","year":"2013","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bbr.2011.07.035","article-title":"Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-\u03b2 peptide in mice","volume":"225","author":"Furukawa-Hibi","year":"2011","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108352_bib47","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0197-0186(97)00124-1","article-title":"Cholinesterase inhibitors for Alzheimer's disease: from tacrine to future applications","volume":"32","author":"Giacobini","year":"1998","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00002093-199806000-00007","article-title":"Safety of tacrine: clinical trials, treatment IND, and postmarketing experience","volume":"12","author":"Gracon","year":"1998","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2020.108352_bib49","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40263-015-0287-2","article-title":"Memantine ER\/donepezil: a review in alzheimer's disease","volume":"29","author":"Greig","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2020.108352_bib50","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0011-393X(03)00059-6","article-title":"Cholinesterase inhibitors for the treatment of Alzheimer's disease: getting on and staying on","volume":"64","author":"Grossberg","year":"2003","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108352_bib51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/gerona\/58.4.M331","article-title":"Management of Alzheimer's disease","volume":"58","author":"Grossberg","year":"2003","journal-title":"J. Gerontol. Med. Sci."},{"key":"10.1016\/j.neuropharm.2020.108352_bib52","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s40263-013-0077-7","article-title":"The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderateto-severe Alzheimer's disease taking cholinesterase inhibitors","volume":"27","author":"Grossberg","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2020.108352_bib53","first-page":"1386","article-title":"Inhibition of cholinesterase by tetrahydroaminacrin","volume":"15","author":"Heilbronn","year":"1961","journal-title":"A. Chem. Snan"},{"key":"10.1016\/j.neuropharm.2020.108352_bib54","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1124\/jpet.105.093047","article-title":"Comparison of Galantamine and Donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats","volume":"316","author":"Hernandez","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108352_bib55","doi-asserted-by":"crossref","first-page":"1171\u20101181","DOI":"10.1016\/S1474-4422(15)00258-6","article-title":"Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses","volume":"14","author":"Howard","year":"2015","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pneurobio.2015.12.003","article-title":"Multitarget compounds bearing tacrine- and donepezil-like structural and functional motifs for the potential treatment of Alzheimer's disease","volume":"151","author":"Ismaili","year":"2017","journal-title":"Prog. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib57","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.brainres.2006.04.073","article-title":"Cerebral ischemia combined with \u03b2-amyloid impairs spatial memory in the eight-arm radial maze task in rats","volume":"1097","author":"Iwasaki","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108352_bib58","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1517\/17425255.4.10.1363","article-title":"Donepezil: potential neuroprotective and disease-modifying effects","volume":"4","author":"Jacobson","year":"2008","journal-title":"Expet Opin. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.20.1.1.34664","article-title":"Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease","volume":"20","author":"Jann","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.neuropharm.2020.108352_bib60","doi-asserted-by":"crossref","first-page":"29\u201031","DOI":"10.1016\/j.phrs.2016.12.033","article-title":"Tacrine: in vivo veritas","volume":"116","author":"Jarrott","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2020.108352_bib61","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s00702-014-1358-0","article-title":"Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials","volume":"122","author":"Jiang","year":"2015","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2020.108352_bib62","doi-asserted-by":"crossref","first-page":"l6217","DOI":"10.1136\/bmj.l6217","article-title":"Cognitive symptoms of Alzheimer's disease: clinical management and prevention","volume":"367","author":"Joe","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2020.108352_bib63","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1196\/annals.1427.036","article-title":"The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration","volume":"1147","author":"Johnson","year":"2008","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.neuropharm.2020.108352_bib64","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","article-title":"The therapeutic potential of the phytocannabinoid cannabidiol for Alzheimer's disease","volume":"28","author":"Karl","year":"2017","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib65","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0404.2011.01525.x","article-title":"Galantamine and behavior in Alzheimer disease: analysis of four trials","volume":"124","author":"Kavanagh","year":"2011","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.neuropharm.2020.108352_bib66","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1111\/bph.14030","article-title":"Beyond symptomatic effects: potential of donepezil as a neuroprotective agent and disease modifier in Alzheimer's disease","volume":"174","author":"Kim","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyv070","article-title":"Protection against brain atrophy by anti-dementia medication in mild cognitive impairment and Alzheimer's disease: meta-analysis of longitudinal randomized placebo-controlled trials","volume":"18","author":"Kishi","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108352_bib68","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1017\/S1461145714000613","article-title":"Galantamine promotes adult hippocampal neurogenesis via M1 muscarinic and \u03b17 nicotinic receptors in mice","volume":"17","author":"Kita","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib69","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000486546","article-title":"A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia","volume":"45","author":"Knight","year":"2018","journal-title":"Dement. Geriatr. Cognit. Disord."},{"key":"10.1016\/j.neuropharm.2020.108352_bib70","series-title":"Pharmacotherapy of Alzheimer's Disease: Current State and Future Perspectives Drug Design and Discovery in Alzheimer's Disease","first-page":"3","author":"Korabecny","year":"2014"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib71","doi-asserted-by":"crossref","first-page":"382","DOI":"10.3390\/ph4020382","article-title":"Neuroactive multifunctional tacrine congeners with cholinesterase, anti-amyloid aggregation and neuroprotective properties","volume":"4","author":"Kozurkova","year":"2011","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib72","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1017\/S1461145705005833","article-title":"Targeting acetylcholinesterase and butyrylcholinesterase in dementia","volume":"9","author":"Lane","year":"2006","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib73","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ejmech.2020.112163","article-title":"Overview of cannabidiol (CBD) and its analogues: Structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer's disease","volume":"192","author":"Li","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib74","first-page":"CD005592","article-title":"Huperzine A for Alzheimer's disease","author":"Li","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"issue":"27","key":"10.1016\/j.neuropharm.2020.108352_bib75","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.2174\/1568026617666170717114944","article-title":"Therapeutic agents in Alzheimer's disease through a multitarge directed ligands strategy: recent progress based on tacrine core","volume":"17","author":"Lin","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib76","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s12974-018-1141-5","article-title":"Galantamine improves cognition, hippocampal inflammation, and synaptic plasticity impairments induced by lipopolysaccharide in mice","volume":"15","author":"Liu","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2020.108352_bib77","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.brainresbull.2019.01.004","article-title":"Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease","volume":"146","author":"Madav","year":"2019","journal-title":"Brain Res. Bull."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2020.108352_bib78","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000051227","article-title":"Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer's disease","volume":"11","author":"Maelicke","year":"2000","journal-title":"Dement. Geriatr. Cognit. Disord."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2020.108352_bib79","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"Maelicke","year":"2010","journal-title":"J. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13024-019-0325-5","article-title":"Neuroimaging biomarkers for alzheimer's disease","volume":"14","author":"M\u00e1rquez","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"13","key":"10.1016\/j.neuropharm.2020.108352_bib81","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1016\/j.bmcl.2012.04.029","article-title":"Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents","volume":"22","author":"Meng","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.neuropharm.2020.108352_bib82","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1185\/030079908X253438","article-title":"Rivastigmine exposure provided by a transdermal patch versus capsules","volume":"23","author":"Mercier","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.neuropharm.2020.108352_bib83","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/nbdi.2001.0462","article-title":"Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain","volume":"9","author":"Mesulam","year":"2002","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib84","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cne.903060202","article-title":"Acetylcholinesterase-rich neurons of the human cerebral cortex: cytoarchitectonic and ontogenetic patterns of distribution","volume":"306","author":"Mesulam","year":"1991","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib86","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/sj.bjp.0706927","article-title":"The anti-amnesic and neuroprotective effects of donepezil against amyloid \u03b225-35 peptide-induced toxicity in mice involve an interaction with the \u03c31receptor","volume":"149","author":"Meunier","year":"2006","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib87","first-page":"51","article-title":"Nose to brain delivery of galantamine loaded nanoparticles: in-vivo pharmacodynamic and biochemical study in mice","volume":"16","author":"Mishra","year":"2019","journal-title":"Curr. Drug Deliv."},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108352_bib88","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/14740338.2017.1351540","article-title":"Acetylcholinesterase inhibitors for treating dementia symptoms- a safety evaluation","volume":"16","author":"Mohammad","year":"2017","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.neuropharm.2020.108352_bib89","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.neurobiolaging.2004.07.015","article-title":"Forebrain acetylcholine regulates adult hippocampal neurogenesis and learning","volume":"26","author":"Mohapel","year":"2005","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.neuropharm.2020.108352_bib90","series-title":"Donepezil Medically Reviewed by Drugs","author":"Multum","year":"2019"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib91","article-title":"A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer's disease","volume":"15","author":"Nordberg","year":"2013","journal-title":"Prim. Care Companion CNS Disord."},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108352_bib92","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1358\/mf.2000.22.8.701373","article-title":"Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro","volume":"22","author":"Ogura","year":"2000","journal-title":"Methods Find Exp. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib93","article-title":"Galantamine for Alzheimer's disease and mild cognitive impairment","volume":"1","author":"Olin","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib94","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2147\/ciia.2007.2.1.17","article-title":"Rivastigmine in the treatment of Alzheimer's disease: an update","volume":"2","author":"Onor","year":"2007","journal-title":"Clin. Interv. Aging"},{"key":"10.1016\/j.neuropharm.2020.108352_bib95","series-title":"Tha Analogs Useful as Cholinesterase inhibitors","author":"Pang","year":"1997"},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib96","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1600-0404.2010.01435.x","article-title":"Changes in CSF acetyl and butyrylcholinesterase activity after long-term treatment with AChE inhibitors in Alzheimer's disease","volume":"124","author":"Parnetti","year":"2011","journal-title":"Acta Neurol. Scand."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib97","doi-asserted-by":"crossref","first-page":"725","DOI":"10.3233\/JAD-200378","article-title":"Effects of citicoline as an adjunct treatment for alzheimer's disease: a systematic review","volume":"76","author":"Piamonte","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108352_bib98","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(00)00064-9","article-title":"Nicotinic receptor subtypes in human brain ageing. Alzheimer and Lewy body diseases","volume":"393","author":"Perry","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib99","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1212\/01.WNL.0000068336.84399.9E","article-title":"Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies","volume":"60","author":"Perry","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108352_bib100","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1021\/jm0340602","article-title":"3-(4-{[benzyl(methyl)amino]methyl}phenyl)-6,7-dimethoxy-2H-2-chromenone(AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy","volume":"46","author":"Piazzi","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib101","doi-asserted-by":"crossref","first-page":"25\u201048","DOI":"10.1016\/j.arr.2016.01.002","article-title":"Brain atrophy in Alzheimer's Disease and aging","volume":"30","author":"Pini","year":"2016","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108352_bib102","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1017\/S1461145701002528","article-title":"Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease","volume":"4","author":"Potkin","year":"2001","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108352_bib103","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1212\/WNL.54.12.2261","article-title":"Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension","volume":"54","author":"Raskind","year":"2000","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.neuropharm.2020.108352_bib104","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1007\/s00702-008-0107-7","article-title":"Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro","volume":"115","author":"Reid","year":"2008","journal-title":"J. Neural. Transm."},{"key":"10.1016\/j.neuropharm.2020.108352_bib105","series-title":"GALANTHAMINE","author":"Rinner","year":"2017"},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108352_bib106","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.bmc.2010.01.071","article-title":"Targeting Alzheimer's disease:Novel indanone hybrids bearing a pharmacophoric fragment of AP2238","volume":"18","author":"Rizzo","year":"2010","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib107","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/gps.2319","article-title":"The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease","volume":"25","author":"Rockwood","year":"2010","journal-title":"Int. J. Geriatr. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108352_bib108","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.phrs.2017.05.005","article-title":"Cannabidiol in medical marijuana: research vistas and potential opportunities","volume":"121","author":"Rong","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.neuropharm.2020.108352_bib109","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1177\/1533317510372923","article-title":"Efficacy and safety of donepezil in patients with Alzheimer's disease in assisted living facilities","volume":"25","author":"Rosenblatt","year":"2010","journal-title":"Am. J. Alzheimer's Dis. Other Dementias"},{"issue":"7184","key":"10.1016\/j.neuropharm.2020.108352_bib110","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1136\/bmj.318.7184.633","article-title":"Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial","volume":"318","author":"Rosler","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.neuropharm.2020.108352_bib111","series-title":"Substituted 1, 2, 3, 4-Tetrahydroquinolin-7-Yl Carbamates Their Preparation and Use There of as Acetylcholinesterase (AChE) Inhibitors for the Treatment of Alzheimer's and Other Neurodegenerative Disease","author":"Roy","year":"2015"},{"key":"10.1016\/j.neuropharm.2020.108352_bib112","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","article-title":"A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol Med","volume":"66","author":"Russo","year":"2006","journal-title":"Hypotheses"},{"key":"10.1016\/j.neuropharm.2020.108352_bib114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejmech.2013.06.021","article-title":"Synthesis, pharmacological assessment, and molecular modeling of 6-chloropyridonepezils: new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease","volume":"67","author":"Samadi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib115","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejmech.2012.09.030","article-title":"Pyridonepezils, new dual AChE inhibitors as potential drugs for the treatment of Alzheimer's disease: synthesis, biological assessment, and molecular modeling","volume":"57","author":"Samadi","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib116","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.ejmech.2016.10.060","article-title":"A review on tacrine-based scaffolds as multi-target drugs (MTDLs) for Alzheimer's disease","volume":"128","author":"Sameem","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108352_bib117","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2174\/1568026619666190128125912","article-title":"Target enzyme in Alzheimer's disease: acetylcholinesterase inhibitors","volume":"19","author":"Saxena","year":"2019","journal-title":"Curr. Top. Med. Chem."},{"issue":"5","key":"10.1016\/j.neuropharm.2020.108352_bib118","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2165\/00003495-200060050-00008","article-title":"Galantamine: a review of its use in Alzheimer's disease","volume":"60","author":"Scott","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.neuropharm.2020.108352_bib119","first-page":"1","article-title":"Galantamine-ER for the treatment of mild-to-moderate Alzheimer's disease","volume":"5","author":"Seltzer","year":"2010","journal-title":"Clin. Interv. Aging"},{"issue":"16","key":"10.1016\/j.neuropharm.2020.108352_bib120","doi-asserted-by":"crossref","first-page":"7646","DOI":"10.1016\/j.bmc.2008.07.014","article-title":"2-Phenoxy-indan-1-one derivatives as acetylcholinesterase inhibitors: a study on the importance of modifications at the side chain on the activity","volume":"16","author":"Shen","year":"2008","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108352_bib121","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1527-3458.2001.tb00204.x","article-title":"Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles","volume":"7","author":"Shigeta","year":"2001","journal-title":"CNS Drug Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib122","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0028-3908(98)00164-6","article-title":"A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066","volume":"38","author":"Snape","year":"1999","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108352_bib123","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.3390\/molecules20034492","article-title":"Multigram synthesis and in vivo efficacy studies of a novel multitarget anti-Alzheimer's compound","volume":"20","author":"Sola","year":"2015","journal-title":"Molecules"},{"issue":"8","key":"10.1016\/j.neuropharm.2020.108352_bib124","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2174\/1567205011310080011","article-title":"A resurrection of 7-MEOTA: a comparison with tacrine","volume":"10","author":"Soukup","year":"2013","journal-title":"Curr. Alzheimer Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.bbr.2004.05.031","article-title":"Spatial discrimination deficits by excitotoxic lesions in the Morris water escape task","volume":"156","author":"Spowart-Manning","year":"2005","journal-title":"Behav. Brain Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1254\/jjp.89.7","article-title":"Research and development of donepezil hydrochloride, a new type of acetylcholinesterase inhibitor","volume":"89","author":"Sugimoto","year":"2002","journal-title":"Jpn. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.neuropharm.2020.108352_bib127","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2174\/1570159X14666151208112754","article-title":"Current treatment options for Alzheimer's disease and Parkinson's disease dementia","volume":"14","author":"Szeto","year":"2016","journal-title":"Curr. Neuropharmacol."},{"issue":"12","key":"10.1016\/j.neuropharm.2020.108352_bib128","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1212\/WNL.54.12.2269","article-title":"A 5-month, randomized, placebo-controlled trial of galantamine in AD","volume":"54","author":"Tariot","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neuropharm.2020.108352_bib129","first-page":"738","article-title":"Two novel donepezil-lipoic acid hybrids: synthesis, anticholinesterase and antioxidant activities and theoretical studies","volume":"29","author":"Terra","year":"2018","journal-title":"J. Braz. Chem. Soc."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib130","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3233\/JAD-190623","article-title":"Volume Analysis of brain cognitive areas in alzheimer's disease: interim 3-year results from the ASCOMALVA trial","volume":"76","author":"Traini","year":"2020","journal-title":"J Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2020.108352_bib131","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jamda.2015.08.007","article-title":"Time to treatment initiation in people with Alzheimer disease: a meta-analysis of randomized controlled trials","volume":"17","author":"Tsoi","year":"2016","journal-title":"J. Am. Med. Dir. Assoc."},{"key":"10.1016\/j.neuropharm.2020.108352_bib132","first-page":"314082","article-title":"The Nrf2\/ARE pathway: a promising target to counteract mitochondrial dysfunction in Parkinson's disease","author":"Tufekci","year":"2011","journal-title":"Parkinsons Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2020.108352_bib133","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/archpsyc.57.2.157","article-title":"Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine Study Group","volume":"57","author":"van Dyck","year":"2000","journal-title":"Arch. Gen. Psychiatr."},{"issue":"6","key":"10.1016\/j.neuropharm.2020.108352_bib134","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2165\/00002512-199404060-00006","article-title":"Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease","volume":"4","author":"Wagstaff","year":"1994","journal-title":"Drugs Aging"},{"issue":"13","key":"10.1016\/j.neuropharm.2020.108352_bib135","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1001\/jama.1994.03510370044030","article-title":"Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease","volume":"271","author":"Watkins","year":"1994","journal-title":"J. Am. Med. Assoc."},{"issue":"7274","key":"10.1016\/j.neuropharm.2020.108352_bib136","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","article-title":"Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group","volume":"321","author":"Wilcock","year":"2000","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108352_bib137","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1002\/gps.409","article-title":"Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease","volume":"16","author":"Wilkinson","year":"2001","journal-title":"Int. J. Geriatr. Psychiatr."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib138","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/(SICI)1097-0282(199601)38:1<109::AID-BIP9>3.0.CO;2-#","article-title":"Binding of tacrine and 6-chlorotacrine by acetylcholinesterase","volume":"38","author":"Wlodek","year":"1996","journal-title":"Biopolymers"},{"issue":"3","key":"10.1016\/j.neuropharm.2020.108352_bib139","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ana.410340312","article-title":"Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability","volume":"34","author":"Wright","year":"1993","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib140","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ejmech.2015.10.001","article-title":"Donepezil-like multifunctional agents:Design, synthesis, molecular modeling and biological evaluation","volume":"121","author":"Wu","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108352_bib141","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.exger.2015.10.015","article-title":"Galantamine attenuates amyloid-\u03b2 deposition and astrocyte activation in APP\/PS1 transgenic mice","volume":"72","author":"Wu","year":"2015","journal-title":"Exp. Gerontol."},{"issue":"1","key":"10.1016\/j.neuropharm.2020.108352_bib142","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0304-3940(02)00830-3","article-title":"Effect of 3-[1-(phenylmethyl)-4-piperidinyl]-1-(2,3,4,5-tetrahydro-1H-1-benzazepin-8-yl)-1-propanone fumarate, a novel acetylcholinesterase inhibitor, on spatial cognitive impairment induced by chronic cerebral hypoperfusion in rats","volume":"331","author":"Xu","year":"2002","journal-title":"Neurosci. Lett."},{"issue":"9","key":"10.1016\/j.neuropharm.2020.108352_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0074916","article-title":"Huperzine A for alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS One"},{"issue":"5\u20136","key":"10.1016\/j.neuropharm.2020.108352_bib144","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/FBP.0b013e3282da278d","article-title":"Anti-dementia drugs and hippocampal-dependent memory in rodents","volume":"18","author":"Yuede","year":"2007","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108352_bib145","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ejmech.2016.03.077","article-title":"Design, synthesis and evaluation of novel tacrine-multialkoxybenzene hybrids as multi-targeted compounds against Alzheimer's disease","volume":"116","author":"Zhang","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2020.108352_bib146","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0304-3940(01)01855-9","article-title":"Huperzine A and donepezil protect rat pheochromocytoma cells against oxygen-glucose deprivation","volume":"306","author":"Zhou","year":"2001","journal-title":"Neurosci. Lett."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390820304202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:12:59Z","timestamp":1758438779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390820304202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":143,"alternative-id":["S0028390820304202"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108352","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108352"}}